Platelet-derived lysophosphatidic acid (LPA) supports the progression of breast and ovarian cancer metastasis to bone. The mechanisms through which LPA promotes bone metastasis formation are, however, unknown. Here we report that silencing of the type 1 LPA receptor (LPA 1) in cancer cells blocks the production of tumor-derived cytokines that are potent activators of osteoclastmediated bone destruction and significantly reduces the progression of osteolytic bone metastases. Moreover, functional blockade of LPA action on its cognate receptor LPA 1 using a pharmacological antagonist mimics the effects of silencing LPA 1 in tumor cells in vitro and substantially reduces bone metastasis progression in animals. Overall, these results suggest that inhibition of plateletderived LPA action on LPA 1 expressed by tumor cells may be a promising therapeutic target for patients with bone metastases.
Platelet-derived lysophosphatidic acid (LPA) supports the progression of breast and ovarian cancer metastasis to bone. The mechanisms through which LPA promotes bone metastasis formation are, however, unknown. Here we report that silencing of the type 1 LPA receptor (LPA 1) in cancer cells blocks the production of tumor-derived cytokines that are potent activators of osteoclastmediated bone destruction and significantly reduces the progression of osteolytic bone metastases. Moreover, functional blockade of LPA action on its cognate receptor LPA 1 using a pharmacological antagonist mimics the effects of silencing LPA 1 in tumor cells in vitro and substantially reduces bone metastasis progression in animals. Overall, these results suggest that inhibition of plateletderived LPA action on LPA 1 expressed by tumor cells may be a promising therapeutic target for patients with bone metastases.
breast cancer ͉ platelet ͉ treatment B one is a frequent metastatic site for many cancers (1) . Bone metastasis formation is associated with a high morbidity rate because of intractable bone pain, pathological fractures, hypercalcemia, and nerve compression (1) . Bone-residing metastatic cells are not directly able to destroy bone. Instead, they secrete paracrine factors [IL-6, IL-8, and parathyroid hormone-related peptide (PTHrP)] that stimulate osteoblast-mediated bone resorption, leading to osteolysis (1) . In this respect, bisphosphonates (as inhibitors of osteoclast activity) are the standard of care in the treatment of patients with bone metastases. Unfortunately, these treatments are only palliative and do not provide a life-prolonging benefit to metastatic patients (2) , indicating that more efficacious therapies are required.
We have recently demonstrated that the naturally occurring bioactive lipid, lysophosphatidic acid (LPA), produced by activated blood platelets (3) , is coopted by breast and ovarian cancer cells as a tumor mitogen and an inducer of tumor-derived cytokine (IL-6 and IL-8) that, altogether, promote the progression of bone metastases (4) . Endogenous receptors through which LPA promotes breast cancer progression and bone metastasis are, however, unknown. LPA binds to three GTPbinding protein-coupled receptors, LPA 1 (5), LPA 2 (6) , and LPA 3 (7) , that mediate the growth factor-like activity of LPA in a large variety of cell types in culture, including cancer cells (8) . Interestingly, mRNA levels for LPA receptors are up-regulated in various cancers (9) (10) (11) ). Yet, the clinical significance of such observations remains to be determined. Using both genetic and pharmacological approaches in vitro and in vivo, we demonstrate here that inhibition of LPA action on its receptor LPA 1 is a promising therapeutic target in cancer, especially for metastasis to bone.
Results

Silencing of LPA1 Expression in Cancer Cells Markedly Impairs Bone
Metastasis Progression. We have shown previously that CHO␤ 3 wt ovarian cancer cells express only LPA 1 (4) . To analyze the role of LPA 1 in bone metastasis formation, we generated a CHO␤ 3 wt cell line in which the expression of LPA 1 was stably downregulated with specific small interference RNAs (siRNAs; see Fig. 1A ). In vivo experiments indicated that the down-regulation of LPA 1 did not alter the propensity of these cells to induce bone metastases in nude mice (Fig. 1B and Table 1 ). However, the silencing of LPA 1 expression markedly reduced (77% inhibition) the progression of osteolytic bone lesions in animals at the time of death (Fig. 1B and Table 1 ). The extent of osteolytic lesions was associated with an increase of the bone volume (BV)͞tissue volume (TV) ratio, which indicated a prevention of bone loss, and with a decrease of the tumor burden (TB)͞TV ratio, which indicated a decrease in skeletal TB (Fig. 1B and Table 1 ). We next focused our attention on the human MDA-BO2 breast cancer cell line, which endogenously expresses all three LPA receptors (LPA 1 , LPA 2 , and LPA 3 ) and induces bone metastases in nude mice (4) . Human MDA-BO2 cells have been previously stably transfected to express GFP (MDA-BO2͞GFP) to detect fluorescent bone metastases in animals (12) . The silencing of LPA 1 expression in MDA-BO2͞GFP cells was achieved by using a siRNA strategy similar to that described for CHO␤ 3 wt cells (Fig. 1 A) . Radiographic analysis indicated that all MDA-BO2͞ GFP transfectants had the same bone metastasis incidence in animals (Table 1) . However, animals injected with MDA-BO2͞ GFP-SiLPA 1 cells displayed an 80% decrease in the extent of osteolytic lesions (Fig. 1C and Table 1 ). Moreover, there was a 50% decrease in the extent of fluorescent lesions in metastatic animals inoculated with MDA-BO2͞GFP-SiLPA 1 cells (Fig. 1C and Table 1 ). Histological examination revealed that the silencing of LPA 1 expression in MDA-BO2͞GFP cells was associated with a decrease of bone destruction (increased BV͞TV ratio) and reduced skeletal TB (decreased TB͞TV ratio; see Fig. 1C and Table 1 ).
LPA1 Controls Tumor Cell Proliferation in Vitro and in Vivo.
To assess whether LPA 1 played a role in tumor cell proliferation, we introduced wild-type cDNA for LPA 1 into the LPA-insensitive human breast cancer SKBr-3 cells (Fig. 2A) . As opposed to parental cells, LPA 1 -expressing SKBr-3 cells (clones #3.1 and #4.1) dose-dependently responded to the mitogenic activity of LPA (Fig. 2B) . Conversely, the silencing of LPA 1 expression in CHO␤ 3 wt cells almost totally abolished the mitogenic activity of LPA on these cells (Fig. 2C) . The silencing of LPA 1 expression also markedly altered the proliferation of MDA-BO2͞GFP cells in response to LPA (Fig. 2D) . In this respect, the residual LPA-dependent proliferation of MDA-BO2͞GFP-SiLPA 1 cells indicated that among LPA receptors, LPA 1 was the main trans-ducer of LPA mitogenic activity on parental cells (Fig. 2D) . We also observed that LPA-dependent MDA-BO2͞GFP cell proliferation was markedly inhibited in the presence of inhibitors for Pi3Kinase (Wortmannin), Gi protein (pertussis toxin), and PKC (chelerythrine chloride) and was totally blocked with inhibitors for mitogen-activated protein kinase (MAPK) kinase kinase, MEK (PD98059), and the Src kinase family (PP2; see Fig. 8A , which is published as supporting information on the PNAS web site). These results suggested that the mitogenic activity of LPA on these cells depended on Src kinase family MAPK extracellular signal-regulated kinase (ERK)1͞2 activation. We therefore investigated the role of LPA 1 on the LPA-dependent activation of ERK1͞2 on MDA-BO2͞GFP-SiLPA 1 and -Sbl clones (Sbl, scrambled). Silencing of LPA 1 expression totally blocked the LPA-dependent phosphorylation of ERK1͞2 (Fig. 8B) . These results, combined with previous observations (Fig. 2D) , demonstrated that the mitogenic activity of LPA, at a concentration of 10 Ϫ7 M, on MDA-BO2͞GFP cells was mediated through a LPA 1 -Src kinase-ERK1͞2-dependent signaling pathway. In vivo, the silencing of LPA 1 markedly inhibited the growth of MDA-BO2͞GFP tumors (80% reduction at day 55; see Fig. 3A ). As judged by Ki67 nuclear antigen staining, the silencing of LPA 1 expression in MDA-BO2͞GFP cells led to a decreased proliferation of both s.c. and skeletal tumors (Fig. 3B) . Thus, we (4) . Among the cytokines, chemokines, and growth factors naturally secreted by MDA-BO2͞GFP cells and detected by RayBio (Norcross, GA) human cytokine antibody arrays, LPA up-regulated the secretion of growth-related oncogene (Gro), granulocyte͞macrophage colony-stimulating factor (GM-CSF), IL-6, IL-8, angiogenin, macrophage chemoattractant protein 1 (MCP-1), and tissue inhibitor of metalloproteinase 1 (TIMP-1) (Fig. 9 , which is published as supporting information on the PNAS web site). Cytokines play a significant role during bone remodeling (1, 14) . Therefore, we examined the effect of LPA 1 expression in tumor cells on the production of IL-6, IL-8, GM-CSF, Gro␣, and MCP-1 ( Table 2) . As opposed to the parental SKBr-3 cell line, which is refractory to LPA-induced cytokine secretion, LPA strongly stimulated the secretion of IL-6, IL-8, GM-CSF, Gro␣, and MCP-1 by LPA 1 -expressing SKBr-3 transfectants (Table 2) . Conversely, the silencing of LPA 1 expression in MDA-BO2͞GFP cells inhibited partially the LPA-dependent secretion of all these cytokines. The residual LPA-dependent cytokine secretion of MDA-BO2͞GFP-SiLPA 1 cells indicated that LPA 1 activity accounted for partial secretion of IL-6 (42%), IL-8 (37%), and GM-CSF (66%), and for almost all of the secretion of Gro␣ (90%) and MCP-1 (95%) by parental cells. Thus, these results indicated that LPA 1 plays a significant role in the LPA-dependent production of proosteoclastic cytokines IL-6, IL-8, GM-CSF, Gro␣, and MCP-1 by tumor cells.
Consistent with this observation, conditioned media collected from LPA 1 -expressing MDA-BO2͞GFP parental mocktransfectant (clone Sbl#9) and SKBr-3͞HA-LPA 1 cells treated with LPA markedly enhanced the differentiation of osteoclasts from bone marrow cells in vitro (Fig. 4A) . In contrast, the The specific production of cytokines secreted in the culture media from cells treated with 1-oleoyl LPA (1 M) for 48 h was quantified by ELISA. Data are expressed as mean Ϯ SD (in pg͞ml per 10 6 cells) of three replicates and are representative of two separate experiments.
conditioned medium collected from LPA-treated MDA-BO2͞ GFP-SiLPA 1 cells did not stimulate osteoclastogenesis nor did the conditioned medium from LPA-treated SKBr-3 cells that lack LPA 1 (Fig. 4A) . These data do not show the functional role of each individual cytokine. However, consistent with an important role of the secretion of IL-6 and IL-8 by tumor cells in osteoclast-mediated bone destruction in vivo (15, 16) , the recruitment of mature osteoclasts located at the bone͞tumor interface of metastatic long bones in animals bearing tumor cells (MDA-BO2͞GFP-SiLPA 1 and CHO␤ 3 wt͞SiLPA 1 cells) that lack LPA 1 was also markedly decreased, as judged by tartrateresistant acid phosphatase (TRAP) staining of bone resorption surfaces (Fig. 4B) . Altogether, these results indicate that LPA 1 expressed by tumor cells mediates LPA action that leads to osteoclast activation in vitro and in vivo.
Pharmacological Blockade of LPA1 Activity Inhibits Bone Metastasis
Progression. 3-(4-[4-([1-(2-chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl]benzylsulfanyl)propanoic acid (Ki16425)
is a potent antagonist of LPA activity on LPA 1 and LPA 3 (17) . Ki16425 blocks the LPA-induced motility of various LPA 1 -expressing carcinoma cell lines in vitro (18) . Ki16425 also dosedependently inhibited LPA-induced proliferation of LPA 1 -expressing MDA-BO2͞GFP and CHO␤ 3 wt cell lines in vitro (Fig. 5) and specifically blocked the LPA-mediated secretion of cytokines (IL-6, IL-8, GM-CSF, Gro␣, and MCP-1) in LPA 1 -expressing breast cancer cell lines (data not shown). We therefore examined the effect of Ki16425 on the progression of established bone metastases using our fluorescent animal model. Ki16425 inhibited by 90% the progression of osteolytic lesions and totally blocked the formation of fluorescent tumor lesions (Fig. 6 ). Histological examination of bone tissue sections showed that bone destruction and skeletal TB were markedly decreased upon Ki16425 treatment (Fig. 6 ). Consistent with in vitro observations, Ki16425 treatment substantially inhibited the recruitment of mature osteoclasts at the bone͞tumor interface and also decreased the in vivo proliferation of tumor cells (80% decrease of the Ki67 cell mitotic index; see Fig. 6 ). Plasma of vehicletreated metastatic mice was as equipotent as purified 1-oleoyl LPA (0.1 M) to stimulate proliferation of tumor cells (Fig. 7A) . In contrast, the mitogenic activity of plasma from Ki16425-treated animals was markedly reduced (80% inhibition; see Fig.  7A ). As indicated in Fig. 7A Inset, the circulating concentration of Ki16425 was 0.1 M in animals treated for 16 days with a daily dose of 20 mg͞kg. In addition, Ki16425 did not affect platelet count after a 16-day treatment of metastatic animals, because the mean Ϯ SD of platelet number per nanoliter was 253.8 Ϯ 32.7 and 261.7 Ϯ 40.7 for vehicle-and Ki16425-treated animals, respectively. Moreover, platelets isolated from Ki16425-treated animals aggregated in response to collagen with the same kinetic and magnitude as platelets isolated from vehicle-treated animals (Fig. 7B ). This rules out a possible antiplatelet activity of this compound. In addition to an absence of side effect of Ki16425 on hemostasis, no alterations of animal weight and behavior have been observed along with treatment. Altogether, these results strongly suggest that the inhibitory activity of Ki16425 on bone metastasis progression is associated with a blockade of plateletderived LPA action on bone residing-tumor cells.
Discussion
Recent studies suggest that LPA plays a significant role in the development of cancers (8) . In breast and ovarian cancer, we have recently demonstrated that LPA produced by blood platelets is a major factor involved in the progression of bone metastases (4). The signaling pathways through which plateletderived LPA promotes bone metastasis are, however, unknown. LPA mediates its activity by binding to G protein-coupled receptors (LPA 1 , LPA 2 , and LPA 3 ; see refs. [5] [6] [7] [8] , and these receptors share signaling pathways, suggesting that their activities might be redundant (19) . The silencing of LPA 1 expression in breast and ovarian cancer cells markedly altered the progression of bone metastases because of inhibition of TB and bone resorption. Our results do not exclude a possible contribution of LPA 2 and LPA 3 in mediating LPA action on bone metastasis progression. Although an artificial overexpression of LPA 1 in human MDA-BO2 cells enhances bone metastasis progression (4), such experimental strategy remains inconclusive on the physiopathological role of endogenous LPA 1 . This LPA receptor was consistently detected at primary and secondary sites of human breast cancers but with no significant variation of expression (9-11). Overexpression of LPA 2 and͞or LPA 3 was observed in several cancers (9) (10) (11) , and these receptors are involved in the LPA-dependent proliferation of colon cancer HCT116 and LS174T cells in vitro (20) , which would suggest that up-regulation of these receptors could play a role in carcinogenesis. However, as shown here, using both genetic and pharmacological approaches, most of the LPA activities on human breast cancer MDA-BO2 cell proliferation and production of proosteoclastic cytokines were LPA 1 -dependent. Silencing of LPA 1 expression decreased TB both in bone and soft tissue, suggesting that the LPA 1 -dependent promoting effect of LPA on tumor growth was independent of the metastatic site. However, bone destruction is mediated by osteoclasts under the control of growth factors and cytokines. Therefore, factors such as LPA that increased tumor cell cytokine secretion might have a more marked influence on the progression of bone metastases than that of metastases located in other organs.
Clinical trials using antiplatelet agents such as aspirin or heparin have yielded inconclusive results (21, 22) . Moreover, bleedings that are frequently encountered in cancer patients treated with cytotoxic chemotherapies because of platelet toxicity often require life-saving transfusions with platelets from healthy donors (23) . We demonstrated here that a specific LPA 1 antagonist exhibited specificity for tumor cell-platelet interaction without abrogating normal platelet functions. Ki16425 blocked in vivo tumor cell proliferation and inhibited the production by tumor cells of proosteoclastic cytokines, whereas normal platelet functions were unaffected. Different antagonists targeting LPA 1 and, to a lesser extent, LPA 3 have been described (17, (24) (25) (26) . In vitro, the concentration of Ki16425 (10 M) used in this study was suitable with a complete inhibition of LPA 1 (Ki, 0.35 M) and LPA 3 (Ki, 0.93 M; see ref. 17) . In contrast, the concentration of Ki16425 (0.1 M) in the plasma of animals treated for 16 days with a daily dose of 20 mg͞kg suggested that the main target in vivo was LPA 1 . In accordance with an involvement of LPA receptors in pathophysiological processes, the treatment of mice with Ki16425 had no obvious deleterious effects, because the animals behaved normally and had normal platelet functions. Altogether, our results demonstrate that LPA 1 expressed by tumor cells plays an essential role in bone metastasis progression and indicate that antagonists blocking LPA 1 -dependent effects of LPA may be promising in the treatment of bone metastasis.
Methods
Cell Culture. Characteristics of SKBr-3, MDA-MB-231͞BO2 (MDA-BO2), MDA-BO2͞GFP, MDA-BO2͞HA-LPA 1 , and CHO␤3wt cell lines were described previously (4, 12, 27) . SKBr-3͞HA-LPA 1 cell lines were established as followed. The cDNA encoding the HA-LPA 1 was removed from the pBiL͞ HA-LPA 1 (4) using NheI and HindIII restriction enzymes. The 5Ј end of the cDNA was blunted by using the T4 DNA polymerase before digestion with HindIII. The vector pCi͞HA-LPA 1 was constructed by inserting the blunt͞HindIII fragment encoding for HA-LPA 1 into the pCi-neo plasmid (Promega), previously digested with SmaI and HindIII restriction enzymes. SKBr-3 cells were transfected with pCi͞HA-LPA 1 using Lipofectamine 2000 (Invitrogen). Cells were cultured for 4 weeks in the presence of G418 (1 mg͞ml), and stable SKBr-3͞HA-LPA 1 clones were isolated by using cloning cylinders. LPA 1 expression was assessed at the mRNA level by real-time quantitative RT-PCR, as described (4), and at the protein level by Western blot analysis with a polyclonal antibody to LPA 1 (Abgent, San Diego). Oleoyl C18:1 LPA (Avanti Polar Lipids) proliferation assays and production of cell conditioned media, as described (4). Ki16425 is a competitive inhibitor of in vitro LPA-dependent signaling pathways through LPA 1 (Ki, 0.35 M), and to a lesser extent, through LPA 3 (Ki, 0.93 M) and LPA 2 (Ki, 6.5 M; see ref. 23 ). Increasing concentrations of Ki16425 (from 10 Ϫ10 to 10 Ϫ5 M) were used in cell proliferation assay in the presence of LPA (10 Ϫ7 M).
Stable Silencing of LPA1 mRNA Expression in Hamster Ovarian and
Human Breast Cancer Cells. We designed small hairpin RNAs (SiRNA) and corresponding SblRNA sequences directed to LPA 1 mRNA target sites based on the human and hamster sequences (GenBank accession nos., NM001401 and AY522544, respectively), using the online SIRNA TARGET DE-SIGNER 1.51 software (Promega). Pairwise oligonucleotides for hamster SiRNA-LPA 1 5Ј-ACCGCCTCTGTCGCCAATCTG-TAAGTTCTCTACAGATTGGCGACAGAGGCTTTTTC-3Ј, 5Ј-TGCAGA A A AAGCCTCTGTCGCCA ATCTGTA- GAGAACTTACAGATTGGCGACAGAGG-3Ј (target nucleotide site: 343-361), and for human SiRNA-LPA 1 5Ј- ACC-GA ATGTCTCGGCATAGT TCA AGT TCTCTGA ACTA-TGCCGAGACATTCTTTTTC-3Ј, 5Ј-TGCAGAAAAAG-A ATGTCTCGGCATAGT TCAGAGA ACT TGA ACTAT-GCCGAGACATT-3Ј (target nucleotide site, 769-786) , as well as sbl control sequences were cloned into the psiSTRIKE puromycin vector containing the U6 promoter (Promega). Plasmids were transfected into tumor cells by using the Transfast reagent (Promega). Cells were cultured for 2 weeks in the presence of puromycin (2 g͞ml), and CHO␤3wt-siLPA 1 , CHO␤3wt-sbl, MDA-BO2͞GFP-siLPA 1 , and MDA-BO2͞GFP-sbl clones were isolated by using cloning cylinders. LPA 1 expression was assessed by real-time RT-PCR and Western blot analysis, as described above.
Cytokine Quantification. Cytokines produced in cell-cultureconditioned media were quantified by ELISA following the manufacturer's instructions (Bender MedSystems, Vienna).
Animal Studies. All procedures were performed on female NMRI nu͞nu mice 4 weeks of age (Janvier, Le Genest St.-Isle, France). Studies involving animals, including housing and care, method of euthanasia, and experimental protocols, were conducted in accordance with a code of practice established by the Experimentation Review Board from the Laënnec School of Medicine. These studies were routinely inspected by the attending veterinarian to ensure continued compliance with the proposed protocols. Bone metastasis and tumorigenesis experiments conducted with MDA-BO2͞GFP cells were as described (4, 28) . Metastatic animals bearing MDA-BO2͞GFP tumors were also treated daily from day 14 to day 30 with Ki16425 by s.c. injection (20 mg͞kg per day). Bone metastasis experiments with CHO␤ 3 wt cells were carried out as described (27) .
Bone Histology and Immunohistochemistry. Quantification of BV͞ TV, TB͞TV, and in situ detection of osteoclasts (TRAP cells) was carried out on undecalcified bone tissue sections, as described (4) . The mitotic index of tumor cells in vivo was quantified by immunohistochemistry by using a mouse anti-human Ki67 monoclonal antibody (Dakocytomation, Dako), as described (4).
Osteoclastogenesis Assay in Vitro. Bone marrow cells from mice were collected, and mononuclear cells were isolated by using lymphocyte separation media (ICN), then seeded in a 48-well tissue culture plate at a density of 2.5 ϫ 10 3 cells per well in ␣-MEM medium (Invitrogen) supplemented with FCS, macrophage-CSF (PreproTech, Rocky Hill, NJ) and receptoractivated nuclear receptor factor B ligand (RANK-L, generous gift of Pr. Jurdic, CNRS, Lyon, France). After incubation for 6 days, differentiated osteoclasts were enumerated under a light microscope as a function of multinucleation (more than three nuclei) and TRAP activity. Results were expressed as the number of osteoclasts per mm 2 .
Platelet Experiments. Blood samples were collected from metastatic mice in the presence of ACD-A as an anticoagulant. Platelets were counted, and aggregation experiments were performed by using washed platelets under stirring conditions at 37°C in the absence or presence of collagen (2.5 g͞ml). Platelet aggregation was monitored over time as the percentage of light transmission, as described (4).
Statistical Analysis. Unpaired Student's t test analyses were carried out by using STAT-VIEW 5.0 software. P Ͻ 0.05 was considered statistically significant.
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